Real-world evidence with a retrospective cohort of 15,968 Andalusian COVID-19 hospitalized patients suggests 21 new effective treatments and one drug that increases death risk.
Loucera, C.; Carmona, R.; Esteban-Medina, M.; Bostelmann, G.; Munoyerro-Muniz, D.; Villegas, R.; Pena-Chilet, M.; Dopazo, J.
Show abstract
Despite the extensive vaccination campaigns in many countries, COVID-19 is still a major worldwide health problem because of its associated morbidity and mortality. Therefore, finding efficient treatments as fast as possible is a pressing need. Drug repurposing constitutes a convenient alternative when the need for new drugs in an unexpected medical scenario is urgent, as is the case with COVID-19. Using data from a central registry of electronic health records (the Andalusian Population Health Database, BPS), the effect of prior consumption of drugs for other indications previous to the hospitalization with respect to patient survival was studied on a retrospective cohort of 15,968 individuals, comprising all COVID-19 patients hospitalized in Andalusia between January and November 2020. Covariate-adjusted hazard ratios and analysis of lymphocyte progression curves support a significant association between consumption of 21 different drugs and better patient survival. Contrarily, one drug, furosemide, displayed a significant increase in patient mortality.
Matching journals
The top 7 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Real world evidence of calcifediol use and mortality rate of COVID-19 hospitalized in a large cohort of 16,401 Andalusian patients 95%
- Machine learning approach to dynamic risk modeling of mortality in COVID-19: a UK Biobank study 94%
- Development and performance of a population-based risk stratification model for COVID-19 94%
Similar papers in this journal
- Efficacy and safety of nitazoxanide combined with ritonavir-boosted atazanavir for the treatment of mild to moderate COVID-19 92%
- Leveraging of SARS-CoV-2 PCR cycle thresholds values (Ct) to forecast COVID-19 trends 92%
- The efficacy of Andrographis paniculata (Burm.f.) Wall. ex Nees crude extract in hospitalised mild COVID-19 patients: a retrospective cohort study 92%
Similar papers in this journal
- Detailed disease progression of 213 patients hospitalized with Covid-19 in the Czech Republic: An exploratory analysis 94%
- Development and validation of a clinical risk score to predict the risk of SARS-CoV-2 infection from administrative data: a population-based cohort study from Italy 94%
- Safety and effectiveness of RBD-specific polyclonal equine F(ab′)2 fragments for the treatment of hospitalized patients with severe Covid-19 disease: a retrospective cohort study 94%
Similar papers in this journal
- Risk factors for severity on admission and the disease progression during hospitalization in a large cohort of COVID-19 patients in Japan 93%
- Development and validation of an algorithm to estimate the risk of severe complications of COVID-19 to prioritise vaccination 92%
- Development and validation of multivariable prediction models for adverse COVID-19 outcomes in IBD patients 92%
Similar papers in this journal
- Evaluation of the current therapeutic approaches for COVID-19: a meta-analysis 91%
- Alpha-1 blockers and susceptibility to COVID-19 in benign prostate hyperplasia patients : an international cohort study 91%
- Empirical evaluation of the sensitivity of background incidence rate characterization for adverse events across an international observational data network 91%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.